Top

Indian Journal of Hematology and Blood Transfusion

13-11-2024 | Thalassemia | CORRESPONDENCE

Evaluating ChatGPT Responses to Questions about Thalassemia

Author: Prerita Mittal

Published in: Indian Journal of Hematology and Blood Transfusion

Excerpt

A Chatbot is an automated computer program that simulates conversations with human users by leveraging natural language processing and machine learning algorithms to comprehend and respond to user inquiries. ChatGPT is an Artificial Intelligence (AI) derived Chatbot that uses Deep learning (DL) technology for information processing [1]. It was developed in November 2022, by OpenAI, San Francisco [2]. …

Chakraborty C, Pal S, Bhattacharya M, Dash S, Lee SS (2023) Overview of Chatbots with special emphasis on artificial intelligence-enabled ChatGPT in medical science. Front Artif Intell 31(6):1237704. https://doi.org/10.3389/frai.2023.1237704CrossRef

Deoghare S (2023) An interesting conversation with ChatGPT about acne vulgaris. Indian Dermatol Online J 15(1):137–140. https://doi.org/10.4103/idoj.idoj_77_23CrossRefPubMedPubMedCentral

Nazir A, Wang Z (2023) A comprehensive survey of ChatGPT: advancements, applications, prospects, and challenges. Meta-Radiol 1(2):100022. https://doi.org/10.1016/j.metrad.2023.100022CrossRefPubMedPubMedCentral

Rao E, Kumar Chandraker S, Misha Singh M, Kumar R (2024) Global distribution of β-thalassemia mutations: an update. Gene 896:148022. https://doi.org/10.1016/j.gene.2023.148022CrossRefPubMed

Title: Evaluating ChatGPT Responses to Questions about Thalassemia
Author: Prerita Mittal
Publication date: 13-11-2024
Publisher: Springer India
Keywords: Thalassemia
Anemia
Published in: Indian Journal of Hematology and Blood Transfusion
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI: https://doi.org/10.1007/s12288-024-01919-3

Elevate your expertise in aplastic anemia (Link opens in a new window)

Aplastic Anemia
Independent Medical Education

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases.

Supported by:

Pfizer

Developed by: Springer Healthcare IME

Learn more

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Targeted Therapy
On-demand webinar

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Podcast | Sexual health in older age

Springer Medicine

Evaluating ChatGPT Responses to Questions about Thalassemia

Excerpt

Elevate your expertise in aplastic anemia (Link opens in a new window)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Podcast | Sexual health in older age

Springer Medicine

Excerpt

Please log in to get access to this content

Elevate your expertise in aplastic anemia (Link opens in a new window)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma